In 2024, 14 pharmacy benefit managers (PBMs) reported receiving payments from pharmaceutical drug manufacturers, which included rebates, fees, and price protection payments.
This year compared to the previous year, PBMs passed $747 million more to issuers, passed $4 million less to enrollees, and retained $51 million less as revenue. They reported $727 million more total collected from pharmaceutical drug manufacturers.
TDI gathers this information under Texas Insurance Code Sections 1369.502 and 1369.503. TDI only reports the data the PBMs supply and doesn't audit it.
Payments from pharmaceutical drug manufacturers
| Amount passed to issuers | $2.82 billion |
| Amount passed to enrollees | $11 million |
| Amount retained as revenue | $40 million |
| Total amount | $2.85 billion |
Note: The “Total amount collected from pharmaceutical drug manufacturers” is lower than expected. Three of the 15 PBMs reported amounts lower than the total of the first three amounts for this question.